Scientific Presentations

Selective Polo-like Kinase 1 (PLK1) Inhibitor PCM-075 is Highly Active Alone and Shows Synergy When Combined with FLT3 Inhibitors in Models of Acute Myeloid Leukemia (AML)

Karena Kosco, Maya Ridinger, Penn Whitley, Antonella Ciavolella, Peter Croucher, Barbara Valsasina, Jeffrey N. Miner, Mark Erlander.


Pharmacodynamic and Tumor Biomarker Analysis of a PLK1 Inhibitor, PCM-075, in a Phase 1b/2 Trial for Acute Myeloid Leukemia

Maya Ridinger, Karena Kosco, Latifa Hassaine, Shiloh Guerrero, Jeffrey N. Miner, Mark Erlander.


Computationally Predicted Sensitivity of Clinical Cohorts Identifies Biomarkers Associated with Response to PCM-075, a PLK-1 Selective Inhibitor

Penn Whitley, Peter J P Croucher, Barbara Valsasina, Dario Ballinari, Italo Beria, Jeffrey N. Miner and Mark G. Erlander.